LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Editas Medicine Inc

Cerrado

SectorSalud

2.26 6.1

Resumen

Variación precio

24h

Actual

Mínimo

2.12

Máximo

2.29

Métricas clave

By Trading Economics

Ingresos

-31M

-76M

Ventas

-26M

4.7M

BPA

-0.92

Margen de beneficio

-1,633.491

Empleados

246

EBITDA

-28M

-72M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+43.38% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

47M

176M

Apertura anterior

-3.84

Cierre anterior

2.26

Noticias sobre sentimiento de mercado

By Acuity

57%

43%

7 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Editas Medicine Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 jun 2025, 20:51 UTC

Ganancias

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 jun 2025, 20:48 UTC

Charlas de Mercado

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 jun 2025, 20:46 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 jun 2025, 20:46 UTC

Charlas de Mercado

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 jun 2025, 19:31 UTC

Charlas de Mercado

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 jun 2025, 19:19 UTC

Charlas de Mercado

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 jun 2025, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 jun 2025, 18:42 UTC

Charlas de Mercado

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 jun 2025, 18:39 UTC

Charlas de Mercado
Ganancias

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 jun 2025, 18:29 UTC

Charlas de Mercado

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 jun 2025, 18:18 UTC

Charlas de Mercado

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 jun 2025, 18:16 UTC

Charlas de Mercado

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 jun 2025, 17:16 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 jun 2025, 17:08 UTC

Ganancias

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 jun 2025, 16:52 UTC

Adquisiciones, fusiones, absorciones

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 jun 2025, 16:22 UTC

Ganancias

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 jun 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 jun 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

27 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

27 jun 2025, 15:59 UTC

Charlas de Mercado

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 jun 2025, 15:56 UTC

Charlas de Mercado

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparación entre iguales

Cambio de precio

Editas Medicine Inc Esperado

Precio Objetivo

By TipRanks

43.38% repunte

Estimación a 12 meses

Media 3.14 USD  43.38%

Máximo 4 USD

Mínimo 1 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Editas Medicine Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

4

Comprar

5

Mantener

1

Vender

Puntuación técnica

By Trading Central

1.33 / 1.54Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

No Evidence

Sentimiento

By Acuity

7 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.